Researchers identify a new way to promote tissue regeneration

Houston Methodist researchers have identified an immune pathway that promotes the formation of a cell that can develop into new tissues and organs. In a new study published in the journal Stem Cells, a team led by John P. Cooke, M.D., Ph.D., chair of Cardiovascular Sciences, Houston Methodist Research Institute, described how activation of innate immunity enhances nuclear reprogramming, one of the first steps in tissue regeneration, or the formation of new tissues and organs from a single cell in the body.

"We found that activating the innate immune system opens up the DNA," said Cooke, the study's senior author. "This open state enhances the formation of induced pluripotent stem cells (iPSCs) or cells that can have the ability to regenerate into other cell types and tissues, such as that of the brain, heart or liver."

The use of iPSCs to generate tissues would revolutionize transplantation, facilitating the growth of artificial organs. Cellular nuclear reprogramming is a powerful tool that enables researchers to direct a skin cell to become another type of tissue or organ. Cooke's team plans to use the activation of innate immunity to regenerate damaged tissues to improve wound healing or recovery after a heart attack.

The research was supported in part by the National Institutes of Health (U01HL100397, HL098049-01A1, and SR00003169/5U01HL099997), the Cancer Prevention and Research Institute of Texas (CPRIT) and the American Heart Association Scientist Development Grant (13SDG17340025).

Sayed N, Ospino F, Himmati F, Lee J, Chanda P, Mocarski ES, Cooke JP.
Retinoic Acid Inducible Gene 1 Protein (RIG1)-like Receptor Pathway is Required for Efficient Nuclear Reprogramming.
Stem Cells. 2017 Mar 9. doi: 10.1002/stem.2607.

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]